Bloomberg News

Pfizer, Mylan Settle With Sanofi Over Epinephrine Injector

February 17, 2012

(Updates with Pfizer comment in third paragraph.)

Feb. 16 (Bloomberg) -- Mylan Inc. and a unit of Pfizer Inc., the world’s largest drugmaker, settled patent litigation with France’s Sanofi over a device used to treat severe allergic reactions.

Sanofi may start selling the device, the Intelliject epinephrine e-cue auto injector, beginning Nov. 15, according to the settlement with Pfizer’s Meridian Medical Technologies, Mylan and Pfizer said in a statement today. The sales are contingent upon final approval from the U.S. Food and Drug Administration.

“We are pleased with this settlement,” said Mylan Chief Executive Officer Heather Bresch. “In addition to our significant efforts in this area, people with life-threatening allergic reactions will benefit from more voices in the fight” against such reactions.

The initial lawsuit was filed in January 2011 in federal court in Wilmington, Delaware, by Meridian, which makes the EpiPen, alleging the Intelliject product would infringe a U.S. patent. Further terms of the settlement weren’t released.

Mylan is based in Canonsburg, Pennsylvania, and Pfizer is based in New York.

The case is King Pharmaceuticals v. Intelliject Inc., 11CV65, U.S. District Court, District of Delaware (Wilmington).To see the patent, click: 7,794,432

--Editors: Mary Romano, David Glovin

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus